California State Teachers Retirement System Decreases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

California State Teachers Retirement System cut its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 7.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 91,998 shares of the biopharmaceutical company’s stock after selling 7,283 shares during the period. California State Teachers Retirement System owned about 0.06% of Ocular Therapeutix worth $786,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Ocular Therapeutix in the fourth quarter valued at $28,000. Atlas Capital Advisors Inc. purchased a new position in Ocular Therapeutix in the fourth quarter valued at $43,000. AlphaQuest LLC purchased a new position in Ocular Therapeutix in the fourth quarter valued at $53,000. Tower Research Capital LLC TRC boosted its holdings in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 8,446 shares during the period. Finally, Walleye Capital LLC purchased a new position in Ocular Therapeutix in the fourth quarter valued at $90,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OCUL has been the subject of a number of recent research reports. William Blair started coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They issued an “outperform” rating for the company. Needham & Company LLC cut their price target on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada started coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus price target of $16.25.

Insider Transactions at Ocular Therapeutix

In other news, Director Richard L. Md Lindstrom bought 10,000 shares of the business’s stock in a transaction dated Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares of the company’s stock, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the sale, the insider now owns 3,499,099 shares in the company, valued at $25,123,530.82. This trade represents a 0.60% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,079 shares of company stock worth $208,739. Corporate insiders own 2.30% of the company’s stock.

Ocular Therapeutix Stock Up 0.1%

Ocular Therapeutix stock opened at $8.91 on Wednesday. The stock’s fifty day moving average is $7.55 and its two-hundred day moving average is $7.89. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a 1-year low of $4.83 and a 1-year high of $11.78. The stock has a market cap of $1.42 billion, a PE ratio of -6.75 and a beta of 1.42.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.